| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Microbiology and Immunology and
Pathology, University of Texas Medical Branch, Galveston, TX 77555
Abs to acetylcholine receptor (AChR) and complement are the major constituents of pathogenic events causing neuromuscular junction destruction in both myasthenia gravis (MG) and experimental autoimmune MG (EAMG). To analyze the differential roles of the classical vs alternative complement pathways in EAMG induction, we immunized C3-/-, C4-/-, C3+/-, and C4+/- mice and their control littermates (C3+/+ and C4+/+ mice) with AChR in CFA. C3-/- and C4-/- mice were resistant to disease, whereas mice heterozygous for C3 or C4 displayed intermediate susceptibility. Although C3-/- and C4-/- mice had anti-AChR Abs in their sera, anti-AChR IgG production by C3-/- mice was significantly suppressed. Both C3-/- and C4-/- mice had reduced levels of B cells and increased expression of apoptotis inducers (Fas ligand, CD69) and apoptotic cells in lymph nodes. Immunofluorescence studies showed that the neuromuscular junction of C3-/- and C4-/- mice lacked C3 or membrane attack complex deposits, despite having IgG deposits, thus providing in vivo evidence for the incapacity of anti-AChR IgGs to induce full-blown EAMG without the aid of complements. The data provide the first direct genetic evidence for the classical complement pathway in the induction of EAMG induced by AChR immunization. Accordingly, severe MG and other Ab- and complement-mediated diseases could be effectively treated by inhibiting C4, thus leaving the alternative complement pathway intact.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  Y. Zhou, B. Gong, F. Lin, R. P. Rother, M. E. Medof, and H. J. Kaminski Anti-C5 Antibody Treatment Ameliorates Weakness in Experimentally Acquired Myasthenia Gravis J. Immunol., December 15, 2007; 179(12): 8562 - 8567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yang, B. Wu, E. Tuzun, S. S. Saini, J. Li, W. Allman, S. Higgs, T. L. Xiao, and P. Christadoss A New Mouse Model of Autoimmune Ocular Myasthenia Gravis Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 5101 - 5111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Sheng, L. Li, B. B. Ganesh, C. Vasu, B. S. Prabhakar, and M. N. Meriggioli Suppression of Experimental Autoimmune Myasthenia Gravis by Granulocyte-Macrophage Colony-Stimulating Factor Is Associated with an Expansion of FoxP3+ Regulatory T Cells J. Immunol., October 15, 2006; 177(8): 5296 - 5306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yang, E. Tuzun, D. Alagappan, X. Yu, B. G. Scott, A. Ischenko, and P. Christadoss IL-1 Receptor Antagonist-Mediated Therapeutic Effect in Murine Myasthenia Gravis Is Associated with Suppressed Serum Proinflammatory Cytokines, C3, and Anti-Acetylcholine Receptor IgG1 J. Immunol., August 1, 2005; 175(3): 2018 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yang, M. Kala, B. G. Scott, E. Goluszko, H. A. Chapman, and P. Christadoss Cathepsin S Is Required for Murine Autoimmune Myasthenia Gravis Pathogenesis J. Immunol., February 1, 2005; 174(3): 1729 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tuzun, B. G. Scott, H. Yang, B. Wu, E. Goluszko, M. Guigneaux, S. Higgs, and P. Christadoss Circulating Immune Complexes Augment Severity of Antibody-Mediated Myasthenia Gravis in Hypogammaglobulinemic RIIIS/J Mice J. Immunol., May 1, 2004; 172(9): 5743 - 5752. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
